

Contents

| | |
|--|-----------|
| List of tables, figures and boxes | vii |
| List of abbreviations | xi |
| Glossary | xiii |
| Foreword | ixx |
| Acknowledgements | xxi |
| 10 key messages | xxiii |
| Introduction | 1 |
| Chapter 1 Background on antibiotics | 9 |
| 1.1 What are antibiotics? | 9 |
| 1.2 Why antibiotics are important | 10 |
| 1.3 Externalities of antibiotics and AR | 11 |
| Chapter 2 Background on AR | 15 |
| 2.1 What is AR? | 15 |
| 2.2 Severity of AR | 16 |
| 2.2.1 AR trends in developed countries | 16 |
| 2.2.2 AR trends in developing countries | 20 |
| 2.3 Clinical and economic impact of AR | 21 |
| 2.3.1 Clinical outcomes | 21 |
| 2.3.2 Costs of resistance | 23 |
| Chapter 3 Causes of AR | 27 |
| 3.1 Misuse of antibiotics | 27 |
| 3.1.1 Physicians and health-care providers | 28 |
| 3.1.2 Livestock and agriculture | 31 |
| 3.2 Role of diagnostics in AR | 32 |
| 3.3 Role of vaccines in AR | 36 |
| 3.3.1 Examples from Europe | 37 |
| 3.3.2 Examples from the United States | 37 |
| 3.4 Lack of new antibiotics | 37 |
| 3.4.1 The antibiotic market | 38 |
| 3.4.2 Areas of unmet need | 43 |
| Chapter 4 Reasons for limited innovation | 49 |
| 4.1 Antibiotic restrictions deter pharmaceutical investment in R&D | 49 |
| 4.2 Challenges in the antibiotics market – NPV | 50 |

| | | |
|---|---|-----|
| 4.3 | Regulatory environment | 53 |
| 4.4 | Estimated cost of drug development | 54 |
| 4.5 | Scientific challenges | 57 |
| Chapter 5 Health system responses to AR | | 59 |
| 5.1 | Examples from Europe | 61 |
| 5.2 | Examples from the United States | 63 |
| Chapter 6 Analysis of opportunities and incentives to stimulate R&D for antibiotics | | 67 |
| 6.1 | Push incentives | 67 |
| 6.1.1 | Increasing access to research | 68 |
| 6.1.2 | Scientific personnel | 71 |
| 6.1.3 | Direct funding of research | 71 |
| 6.1.4 | Translational research | 77 |
| 6.1.5 | Tax incentives | 79 |
| 6.1.6 | PDPs | 83 |
| 6.2 | Pull incentives | 89 |
| 6.2.1 | Monetary prizes | 89 |
| 6.2.2 | Advance market commitments | 95 |
| 6.2.3 | Patent buyout | 100 |
| 6.3 | Lego-regulatory mechanisms | 100 |
| 6.3.1 | Clinical trials | 101 |
| 6.3.2 | Intellectual property mechanisms | 106 |
| 6.3.3 | Expedited regulatory review | 117 |
| 6.3.4 | Pricing and reimbursement | 121 |
| 6.3.5 | Liability protection | 126 |
| 6.3.6 | Antitrust laws | 127 |
| 6.3.7 | <i>Sui generis</i> rights | 127 |
| 6.4 | Combined push-pull incentive models | 128 |
| 6.4.1 | Orphan drug designation | 128 |
| 6.4.2 | Call options for antibiotics model | 129 |
| Chapter 7 Conclusions | | 137 |
| 7.1 | Rationale for intervention in the antibiotics market | 137 |
| 7.2 | Preserving the effective life of existing and new antibiotics | 139 |
| 7.3 | Key concepts in incentive design | 141 |
| 7.4 | Conclusions on individual incentives | 147 |
| 7.4.1 | Direct public subsidy for basic research | 147 |
| Appendix A. EU Council conclusions on innovative incentives | | 159 |
| Appendix B. US-EU joint declaration on creation of transatlantic taskforce on antimicrobial resistance | | 161 |
| Appendix C. Global vaccine research | | 175 |
| Appendix D. Possible funding mechanisms for a COA scheme | | 177 |
| References | | 179 |